Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells
出版年份 2019 全文链接
标题
Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells
作者
关键词
-
出版物
Cancers
Volume 11, Issue 9, Pages 1330
出版商
MDPI AG
发表日期
2019-09-09
DOI
10.3390/cancers11091330
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients
- (2019) Manuel Gentiluomo et al. CARCINOGENESIS
- Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer
- (2019) Khine Myint et al. Scientific Reports
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- A phosphotyrosine switch regulates organic cation transporters
- (2016) Jason A. Sprowl et al. Nature Communications
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles
- (2015) Khine Myint et al. PLoS One
- Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo
- (2014) Chaa odong Li et al. Biotechnology Journal
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons
- (2012) Johnson J. Liu et al. BIOCHEMICAL PHARMACOLOGY
- Polymorphic Transporters and Platinum Pharmacodynamics
- (2012) Jason A. Sprowl et al. Drug Metabolism and Pharmacokinetics
- Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression
- (2012) Ke Shen et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Drug transporters of platinum-based anticancer agents and their clinical significance
- (2011) Herman Burger et al. DRUG RESISTANCE UPDATES
- Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation
- (2011) C. Mohn et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons
- (2011) N. N. Jong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction and Identification of Drug Interactions with the Human ATP-Binding Cassette Transporter Multidrug-Resistance Associated Protein 2 (MRP2; ABCC2)
- (2008) Jenny M. Pedersen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
- (2007) Matthew D. Hall et al. Annual Review of Pharmacology and Toxicology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started